Veru Inc News

Veru Inc | DEFA14A: Others

May 9 13:08 ET

Veru Inc | DEFR14A: Definitive proxy statement in connection with contested solicitations

May 9 13:07 ET

Veru Inc | 8-K: Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 8 07:03 ET

Veru Inc | 8-K: Forbearance Agreement

Apr 26 16:30 ET

Veru Inc | 8-K: Veru Inc Regains Compliance with Nasdaq's Listing Requirements

Apr 25 07:05 ET

Veru Inc | DEFA14A: Others

Apr 1 16:34 ET

Veru Inc | DEFA14A: Others

Mar 22 16:53 ET

Veru Inc | 8-K: Current report

Feb 28 12:30 ET

Veru Inc | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Feb 15 16:54 ET

Veru Inc | 8-K: Current report

Feb 15 16:11 ET

Veru Inc | 8-K: Veru Inc Announces First Quarter FY2024 Financial Highlights

Feb 8 07:05 ET

Veru Inc | 8-K: Current report

Jan 26 16:13 ET

Veru Inc | DEFA14A: Others

Jan 26 09:04 ET

Veru Inc | DEF 14A: Definitive information statements

Jan 26 09:04 ET

Veru Inc | 8-K: Veru Inc Entered into an Underwriting Agreement and Announced Pricing of Public Offering of Common Stock

Dec 18, 2023 09:01 ET

Veru Inc | 8-K: Amendment of a Common Stock Purchase Agreement and Update of the Presentation of 「Discussion Planned Development of Enobosarm Initially as a Treatment」

Dec 13, 2023 16:04 ET

Veru Inc | 8-K: Current report

Nov 15, 2023 16:50 ET

Veru Inc | 8-K: Amendment to Asset Purchase Agreement

Oct 2, 2023 17:23 ET

Veru Inc | 8-K: Veru Inc Announced Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

Sep 11, 2023 07:00 ET

Veru Inc | 8-K: Veru Inc Reports Fiscal 2023 Third Quarter Financial Results

Aug 10, 2023 07:00 ET